Relative Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of Finerenone 20 mg as Suspension (Pediatric Formulation), Intact Tablet and Crushed Tablet (Adult Formulation) in the Fasting Condition, and to Investigate the Effect of a High Fat, High Calorie Meal on the Suspension in Healthy Male Subjects in a Randomized, Open-label, Four-fold Crossover Design.
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Finerenone (Primary) ; Finerenone (Primary)
- Indications Chronic heart failure; Diabetic nephropathies
- Focus Pharmacokinetics
- Sponsors Bayer
- 16 Mar 2017 Status changed from active, no longer recruiting to completed.
- 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2016 Status changed from not yet recruiting to recruiting.